Page last updated: 2024-09-03

dx 9065a and Hemorrhage

dx 9065a has been researched along with Hemorrhage in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alexander, JH; Armstrong, PW; Becker, RC; Berger, PB; Bovill, EG; Burton, JR; Cohen, EA; Dyke, CK; Goodman, S; Harrington, RA; Hochman, JS; Kawai, C; Kleiman, NS; Kodama, K; Lincoff, AM; Yang, H	1
Hara, T; Kunitada, S; Morishima, Y; Tanabe, K; Terada, Y	1
Aoyagi, K; Hara, T; Kondo, T; Kunitada, S; Morishima, Y; Shibutani, T; Shinohara, Y; Tanabe, K; Terada, Y	1

Trials

1 trial(s) available for dx 9065a and Hemorrhage

Article	Year
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Naphthalenes; Partial Thromboplastin Time; Propionates; Serine Endopeptidases	2005

Article

Year

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.

Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:3

Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Naphthalenes; Partial Thromboplastin Time; Propionates; Serine Endopeptidases

2005

Other Studies

2 other study(ies) available for dx 9065a and Hemorrhage

Article	Year
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thrombosis and haemostasis, 1997, Volume: 78, Issue:5 Topics: Animals; Anticoagulants; Antithrombin III; Arginine; Bleeding Time; Blood Coagulation; Disease Models, Animal; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Male; Naphthalenes; Peptide Hydrolases; Pipecolic Acids; Propionates; Rats; Rats, Wistar; Sulfonamides; Thrombin; Thrombosis	1997
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model. Thrombosis and haemostasis, 1999, Volume: 81, Issue:5 Topics: Administration, Oral; Animals; Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Male; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Rats; Rats, Wistar; Stomach Ulcer; Tail; Thrombosis	1999

Article

Year

Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.

Thrombosis and haemostasis, 1997, Volume: 78, Issue:5

Topics: Animals; Anticoagulants; Antithrombin III; Arginine; Bleeding Time; Blood Coagulation; Disease Models, Animal; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Male; Naphthalenes; Peptide Hydrolases; Pipecolic Acids; Propionates; Rats; Rats, Wistar; Sulfonamides; Thrombin; Thrombosis

1997

DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.

Thrombosis and haemostasis, 1999, Volume: 81, Issue:5

Topics: Administration, Oral; Animals; Anticoagulants; Factor Xa Inhibitors; Hemorrhage; Male; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Rats; Rats, Wistar; Stomach Ulcer; Tail; Thrombosis

1999